Quick Answer
Camp4 Therapeutics Corp reported Cash and Equivalents of $109.52 million for fiscal year 2025.
Camp4 Therapeutics Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $109.52M | +71.0% |
| 2024 | $64.04M | +66.9% |
| 2023 | $38.38M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $75.25M | +2876.9% | +92.7% |
| June 30, 2025 | $39.05M | — | -20.8% |
| March 31, 2025 | $49.32M | — | -23.0% |
| December 31, 2024 | $64.04M | +66.9% | +2433.2% |
| September 30, 2024 | $2.53M | -95.0% | -93.4% |
| December 31, 2023 | $38.38M | — | -24.0% |
| September 30, 2023 | $50.47M | — | — |
- Camp4 Therapeutics Corp showed an increase of +71.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Camp4 Therapeutics Corp’s cash and equivalents has grown by 185.3% (from $38.38 million to $109.52 million).
- The most recent figure is from Camp4 Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: